Join Professor John Camm and Professor John Eikelboom in their discussion of the association between bleeding occurrence and new cancer diagnosis among patients with atherosclerosis receiving antithrombotic therapy.
The COMPASS trial, involving over 27,000 patients, investigated whether rivaroxaban alone or rivaroxaban in combination with aspirin, would be more effective than aspirin alone for secondary cardiovascular prevention in patients with stable atherosclerotic vascular disease. Additionally, the association between bleeding occurrence and new cancer diagnosis in these patients was evaluated, which is what this 30-minute journal club explores and discusses.
Register your email and provide your feedback
To help measure the effectiveness of this NOAC Education module, please enter your email below to take part in a short follow-up survey